Researchers have developed a liquid gel that solidifies upon injection into solid tumors, presenting a potential treatment for metastatic cancers. This innovative gel, visible on CT scans, provides slow-release cancer-fighting treatments, and when combined with immunotherapy, it demonstrated promising results in preclinical models, inducing tumor regression and enhancing survival.
The Mass General Brigham research team collaborated with the Koch Institute for Integrative Cancer Research to develop a gel delivery system for direct injection of cancer drugs into tumors. This addresses challenges faced by intratumoral therapy, offering precise drug delivery and controlled release. The gel solidifies upon delivery, contains an imaging agent for visibility on CT scans, and can maintain a high concentration of drugs for controlled release.
The interdisciplinary research team, comprising engineers and medical professionals, optimized the gel’s delivery system in the laboratory and tested its effectiveness. Results showed improved survival rates in both colon and breast cancer models, with complete regression observed in responders at both the treated and distant tumor sites. The potential application of this technology is being pursued for clinical use, although further safety testing is required before broader evaluation of drug efficacy.
The findings of the research team were published in the journal Advanced Healthcare Materials. This innovative approach to intratumoral cancer immunotherapy could have significant implications for the future of cancer treatment.
I have over 10 years of experience in the cryptocurrency industry and I have been on the list of the top authors on LinkedIn for the past 5 years. I have a wealth of knowledge to share with my readers, and my goal is to help them navigate the ever-changing world of cryptocurrencies.
